Adrian Rawcliffe

CIK 1555851 · Chief Executive Officer · last filed 2025-12-10

Adrian Rawcliffe is a Chief Executive Officer who has filed 53 SEC Form 4 insider transactions across 3 companies since 2016. The most recent filing, for WVE, was dated Dec 10, 2025. Across all open-market trades the lifetime net is −$2.3M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.2M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$1.17M

Companies

3

Total Filings

53

Lifetime Open-Market Net

-$2.30M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
WVE Director 54,700 $5.89 $322.2K -$739.4K 12 2025-12-10
Adaptimmune Therapeutics PLC (ADAP) Delisted Chief Executive Officer 44,327 $0.06 $2.6K -$518.7K 30 2025-02-20
ASND CEO and CFO 3,318 $254.44 $844.2K -$1.04M 7 2019-09-03

Recent Filings

53 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2025-12-10 WVE Mixed -$379.3K EDGAR
2025-12-08 WVE Notice (144) −42,000 -$314.6K EDGAR
2025-11-14 WVE Sell (S) −16,115 -$109.4K EDGAR
2025-11-13 WVE Notice (144) −16,115 -$112.1K EDGAR
2025-08-13 WVE Grant (A) +12,700 $0 EDGAR
2025-02-20 Adaptimmune Therapeutics PLC (ADAP) Delisted Grant (A) $0 EDGAR
2025-01-17 Notice (144) −30,601 -$17.8K EDGAR
2025-01-17 Adaptimmune Therapeutics PLC (ADAP) Delisted Sell (S) −30,601 -$17.8K EDGAR
2025-01-15 Notice (144) −30,473 -$17.9K EDGAR
2025-01-15 Adaptimmune Therapeutics PLC (ADAP) Delisted Sell (S) −59,569 -$34.6K EDGAR
Showing 110 of 53
Page 1 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.